| abstract |
The present invention relates to novel crystalline forms of vilanterol trifenatate, processes for their preparation, and their use in a pharmaceutical composition for the treatment of respiratory diseases, particularly for the treatment of asthma and chronic obstructive pulmonary disease. . In particular, the present invention relates to a crystalline form of vilanterol trifenatate characterized in that the form has an XRPD motif, as defined in the invention, which has characteristic diffraction angles (2-theta or 2Θ (°)) falling within or at each end of one or more of the following ranges: (a) 3 to 5 °, such as 3.8 to 4.4 °; and / or (b) 7 to 9.9 °, such as 7 to 8.5 °; and / or (c) 12 to 13.3 °, such as 12 to 13.3 °; and / or (d) 16.4 to 17.3 °, such as 16.4 to 17.3 °; and / or (e) 26.8 to 28.3 °, such as 26.8 to 28.3 °. |